Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$51.08 USD
+0.11 (0.22%)
Updated Jul 9, 2024 04:00 PM ET
Pre-Market: $51.30 +0.22 (0.43%) 9:26 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Earnings News For CRBP
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
-
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?